{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:25:46Z","timestamp":1779110746383,"version":"3.51.4"},"reference-count":50,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular disease. The treatment of arthritis by tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors may decrease the serum concentrations of vascular biomarkers. We determined circulating levels of oxidized low-density lipoprotein (oxLDL)\/\u03b2<jats:sub>2<\/jats:sub> glycoprotein I (\u03b2<jats:sub>2<\/jats:sub>-GPI) complexes, antibodies to 60 kDa heat shock protein (anti-Hsp60), soluble urokinase plasminogen activator receptor (suPAR), and B-type natriuretic peptide (BNP) fragment in sera of RA and AS patients undergoing anti-TNF treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Fifty-three patients with RA\/AS were treated with etanercept or certolizumab pegol for 1 year. Circulating oxLDL\/\u03b2<jats:sub>2<\/jats:sub>-GPI complex (AtherOx), anti-Hsp60 IgG, and BNP8-29 fragment levels were assessed by ELISA. suPAR levels were determined by suPARnostic Quick Triage test. Flow-mediated vasodilation (FMD), carotid intima-media thickness (CIMT), and arterial pulse wave velocity (PWV) were determined by ultrasound.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>One-year anti-TNF treatment significantly decreased oxLDL\/\u03b2<jats:sub>2<\/jats:sub>-GPI levels, as well as suPAR levels in patients with critically high suPAR levels at baseline. In RA, BNP levels were higher in seropositive vs seronegative patients. Serum levels of these vascular biomarkers variably correlated with lipids, anticitrullinated protein antibodies, rheumatoid factor, and C-reactive protein. CIMT positively correlated with BNP, and PWV with suPAR and anti-Hsp60, whereas FMD inversely associated with anti-Hsp60. In repeated measures ANOVA analysis, disease activity supported the effects of anti-TNF treatment on 12-month changes in oxLDL\/\u03b2<jats:sub>2<\/jats:sub>-GPI. CIMT supported the effects of therapy on changes in anti-Hsp60 and suPAR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>These biomarkers may be involved in the pathogenesis of atherosclerosis underlying RA\/AS. TNF inhibition variably affects the serum levels of oxLDL\/\u03b2<jats:sub>2<\/jats:sub>-GPI, suPAR, and BNP.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.200916","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T22:36:42Z","timestamp":1608158202000},"page":"821-828","source":"Crossref","is-referenced-by-count":10,"title":["Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of 1-year Antitumor Necrosis Factor-\u03b1 Therapy"],"prefix":"10.3899","volume":"48","author":[{"given":"Anita","family":"Pusztai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Hamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Guly\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"V\u00e9gh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00f3ra","family":"Bodn\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Kerekes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Cz\u00f3kolyov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szilvia","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levente","family":"Bodoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Hodosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Domj\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2943-2750","authenticated-orcid":false,"given":"G\u00e1bor","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibolya","family":"Sz\u00f6ll\u0151si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis R.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1ndor","family":"Sz\u00e1nt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-7719","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-6844","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-9531","authenticated-orcid":false,"given":"Gabriella","family":"Sz\u0171cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"2022062114101737000_48.6.821.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209775"},{"key":"2022062114101737000_48.6.821.2","first-page":"398","article-title":"Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity","volume":"35","author":"Kerekes","year":"2008","journal-title":"J Rheumatol"},{"key":"2022062114101737000_48.6.821.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100668"},{"key":"2022062114101737000_48.6.821.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.112"},{"key":"2022062114101737000_48.6.821.5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.autrev.2016.07.026","article-title":"Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers","volume":"15","author":"L\u00f3pez-Mejias","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2022062114101737000_48.6.821.6","first-page":"147","article-title":"Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis","volume":"13","author":"Kerekes","year":"2011","journal-title":"Isr Med Assoc J"},{"key":"2022062114101737000_48.6.821.7","first-page":"373","article-title":"Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis","volume":"24","author":"Gonzalez-Gay","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114101737000_48.6.821.8","doi-asserted-by":"crossref","first-page":"102514","DOI":"10.1016\/j.autrev.2020.102514","article-title":"Usefulness of vasculitis biomarkers in the era of the personalized medicine","volume":"19","author":"Csernok","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2022062114101737000_48.6.821.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.06.003"},{"key":"2022062114101737000_48.6.821.10","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2000.0393"},{"key":"2022062114101737000_48.6.821.11","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.028"},{"key":"2022062114101737000_48.6.821.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.d01-1019.x"},{"key":"2022062114101737000_48.6.821.13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.autrev.2017.11.028","article-title":"Oxidized low density lipoproteins: the bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders","volume":"17","author":"Suciu","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2022062114101737000_48.6.821.14","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311398884"},{"key":"2022062114101737000_48.6.821.15","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu1011oa"},{"key":"2022062114101737000_48.6.821.16","doi-asserted-by":"publisher","DOI":"10.1078\/0171-2985-00214"},{"key":"2022062114101737000_48.6.821.17","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2211oa"},{"key":"2022062114101737000_48.6.821.18","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP88WVRDRDFBAS"},{"key":"2022062114101737000_48.6.821.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-008-8096-8"},{"key":"2022062114101737000_48.6.821.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1990.tb02770.x"},{"key":"2022062114101737000_48.6.821.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2001.00819.x"},{"key":"2022062114101737000_48.6.821.22","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.042"},{"key":"2022062114101737000_48.6.821.23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jbspin.2011.03.010","article-title":"Anti-mutated citrullinated vimentin (anti-MCV) and anti-65 kDa heat shock protein (anti-Hsp65): new biomarkers in ankylosing spondylitis","volume":"79","author":"Bodn\u00e1r","year":"2012","journal-title":"Joint Bone Spine"},{"key":"2022062114101737000_48.6.821.24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12192-018-0951-9","article-title":"Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis","volume":"24","author":"Mantej","year":"2019","journal-title":"Cell Stress Chaperones"},{"key":"2022062114101737000_48.6.821.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(00)00287-X"},{"key":"2022062114101737000_48.6.821.26","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.50.4.314"},{"key":"2022062114101737000_48.6.821.27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2018.05.016","article-title":"uPA\/uPAR signaling in rheumatoid arthritis: shedding light on its mechanism of action","volume":"134","author":"Dinesh","year":"2018","journal-title":"Pharmacol Res"},{"key":"2022062114101737000_48.6.821.28","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2821"},{"key":"2022062114101737000_48.6.821.29","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1515\/cclm-2015-0079","article-title":"Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis","volume":"53","author":"Legany","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2022062114101737000_48.6.821.30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1515\/cclm-2012-0221","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission","volume":"51","author":"Toldi","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"2022062114101737000_48.6.821.31","first-page":"122","article-title":"The clinical value of soluble urokinase plasminogen activator receptor (suPAR) levels in autoimmune connective tissue disorders","volume":"27","author":"Vasarhelyi","year":"2016","journal-title":"EJIFCC"},{"key":"2022062114101737000_48.6.821.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.8.488"},{"key":"2022062114101737000_48.6.821.33","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.071233"},{"key":"2022062114101737000_48.6.821.34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejim.2018.10.013","article-title":"Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: a prospective study","volume":"60","author":"Bosello","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2022062114101737000_48.6.821.35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijcard.2016.08.246","article-title":"N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis","volume":"223","author":"Allanore","year":"2016","journal-title":"Int J Cardiol"},{"key":"2022062114101737000_48.6.821.36","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.2174\/0929867322666150209160701","article-title":"Tumor necrosis factor blocking therapy and congestive heart failure in patients with inflammatory rheumatic disorders: a systematic review","volume":"22","author":"Heslinga","year":"2015","journal-title":"Curr Med Chem"},{"key":"2022062114101737000_48.6.821.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.119412"},{"key":"2022062114101737000_48.6.821.38","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/11.9.1363"},{"key":"2022062114101737000_48.6.821.39","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1118-y"},{"key":"2022062114101737000_48.6.821.40","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282f314f7"},{"key":"2022062114101737000_48.6.821.41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-019-04497-0","article-title":"Effects of 1-year anti-TNF-\u03b1 therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis","volume":"40","author":"V\u00e9gh","year":"2020","journal-title":"Rheumatol Int"},{"key":"2022062114101737000_48.6.821.42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/08916930902828247","article-title":"OxLDL\/beta2GPI complex and anti-oxLDL\/beta2GPI in SLE: prevalence and correlates","volume":"42","author":"Bassi","year":"2009","journal-title":"Autoimmunity"},{"key":"2022062114101737000_48.6.821.43","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jbspin.2012.06.023","article-title":"Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis","volume":"80","author":"Toldi","year":"2013","journal-title":"Joint Bone Spine"},{"key":"2022062114101737000_48.6.821.44","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.699549"},{"key":"2022062114101737000_48.6.821.45","first-page":"811","article-title":"Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population","volume":"29","author":"Koga","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114101737000_48.6.821.46","doi-asserted-by":"publisher","DOI":"10.1891\/0730-0832.34.6.355"},{"key":"2022062114101737000_48.6.821.47","first-page":"761","article-title":"Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis","volume":"31","author":"L\u00f3pez-Mej\u00edas","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114101737000_48.6.821.48","first-page":"311","article-title":"Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis","volume":"26","author":"Gonzalez-Gay","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114101737000_48.6.821.49","first-page":"640","article-title":"Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-alpha antagonist therapy","volume":"32","author":"Genre","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114101737000_48.6.821.50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/ROM.1000169","article-title":"Effects of one-year anti-TNF-\u03b1 therapy on biomarkers of angiogenesis and functional vascular parameters in arthritides","volume":"4","author":"Balogh","year":"2019","journal-title":"Rheumatol Orthop Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.200916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:12:33Z","timestamp":1655845953000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.200916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.3899\/jrheum.200916"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.200916","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}